News & Updates
Filter by Specialty:
Baricitinib keeps radiographic progression levels low in rheumatoid arthritis
Treatment with oral baricitinib steadily inhibits radiographic progression of structural joint damage in most patients with rheumatoid arthritis (RA), while achieving clinical improvement in disease activity, through 5 years as compared with initial conventional synthetic disease-modifying antirheumatic drug (csDMARD) or placebo, results of a study have shown.
Baricitinib keeps radiographic progression levels low in rheumatoid arthritis
24 Feb 2022
Add-on trilaciclib boosts antitumour effects of chemo combinations for triple-negative breast cancer
Pretreatment with the cyclin-dependent kinase 4/6 inhibitor trilaciclib appears to enhance the antitumour efficacy of gemcitabine plus carboplatin, with significant survival gains for patients with metastatic triple-negative breast cancer (mTNBC), according to the results of a phase II trial.
Add-on trilaciclib boosts antitumour effects of chemo combinations for triple-negative breast cancer
24 Feb 2022
Dysglycaemia may increase likelihood of deterioration in non-severe COVID-19 patients
Patients with non-severe coronavirus disease 2019 (COVID-19) who have worse glycaemic status are more likely to deteriorate clinically, but glycaemic status does not adversely impact neutralizing antibody (NAb) responses, researchers from the University of Hong Kong have shown.
Dysglycaemia may increase likelihood of deterioration in non-severe COVID-19 patients
24 Feb 2022
Tenecteplase still feasible up to 24 hours after a stroke
Intravenous thrombolysis with tenecteplase up to 24 hours after a stroke appears to re-establish blood flow in patients with large-vessel acute ischaemic stroke selected with advanced imaging, the phase IIa CHABLIS-T study has shown.